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ABSTRACTS  
Endophytic fungi are abundant and have been found asymptomatically in most plants species. Endophytic fungi are 
considered as hidden members of the microbial world and represent an under-utilized resource of natural bioactive 
compounds for agricultural, industrial and medicinal uses. As reported previously, several valuable natural products with 
anticancer, antimicrobial, and insecticidal properties have been successfully extracted from the endophytic fungi. 
Chemotherapy yields the first promise of destroying cancer cells that has distributed into the body. This is due to the fact 
that chemotherapeutic agents overlap with the process of dividing cancer cells, which in turn leads to establishing new 
cells. Vincristine (vinca alkaloids) and podophyllotoxin prohibit the microtubules polymerization at high drug 
concentrations whereas Taxol™ and Taxotere stimulate the microtubules polymerization and stabilize the microtubules as 
well at high concentrations. In This review, we critically attempt to summarize the mechanisms of the cancer 
chemotherapeutic drugs, namely, Taxol and Vincristine (vinca alkaloids) on the need for more the research in the field of 
cancer chemotherapy. 
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INTRODUCTION 
Microorganisms are rich sources for natural products with large possibility for discovering of new molecules towards using 
them as anticancer drugs1,4. The popularity of complementary and alternative medicine have increased in recent decades 5. 
A significant role of drugs, derived from natural sources, has been detected for prevention and treatment of diseases. More 
than 70% of the antimicrobial and 60% of the anticancer drugs currently in clinical use are natural products or have been 
developed from natural products 6. In the recent years, researchers are directed towards investigation the different novel 
natural bioactive products from plants 7. According to Lam 8, there was declining in the discovery and development of 
novel chemical entities. Therefore, the recent trends are to maximize the revelation of new bioactive metabolites 9.  
During the last 20 years, the majority of novel biochemistry and secondary metabolites were obtained from microorganisms 
which reside in the plant tissues 1, 3. Endophyte term was used by mycologist for fungi that live in the intercellular spaces 
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of healthy host tissues of plants without causing over symptoms on the plants 10,12. No doubt, exploiting a variety of new 
natural products from endophytic fungi has become a hot spot of new drug research. Endophytic fungi have potential 
applications value in various fields such as medicine, food industry and agriculture 13, 14. After discovering paclitaxel in 
1993 15, there have been a growing interest in the studying of endophytic fungi by scientists as potential producers of 
various types of biologically active compounds. Many valuable bioactive compounds with antimicrobial, insecticidal, 
cytotoxic, and anticancer activities have been successfully discovered from endophytic fungi. These bioactive compounds 
are categorized as lactones, alkaloids, terpenoids, quinones, steroids, phenols and lignans 16, 17. Taxol, Camptothecin, 
Podophyllotoxin, Torreyanic acid, Galioclladicillins A and B and Vincristine (vinca alkaloids) isolated from Taxus 
brevifolia, Camptotheca acuminota, Trametes hirsute, Pestalotiopsis microspore, Alternaria alternata and Fusarium 
oxysporum accordingly have been used as anticancer agents for treating various kinds of cancer.  
Cancer is a class of disease by which abnormal growth of cells are able to divide uncontrollably and invade other tissues. 
Cancer was reported to cause about 13% of all deaths worldwide in 2007, making it a leading cause of death worldwide. 
Liver, Lung, colon, stomach and breast cancer are considered as the main kinds of cancer that cause to the total death 
worldwide. Described as one of the principle methods of treatment for cancer patients, Chemotherapy is the process of 
using anti-cancer agents to block cells from multiplying and dividing 18. Chemotherapeutic agents are defined as the drugs 
that block the growth and spread of cancer cells by interfering with specific molecules involved in tumour growth and 
progression. The primary goal of targeted therapy is to fight cancer cells with more precision and potentially fewer side 
effects 19. The use of chemotherapy to treat cancer began at the start of the 20th century with attempts to narrow the universe 
of chemicals that might affect the disease by developing methods to screen chemicals using transplantable tumors in 
rodents. Recently, chemotherapy has changed as important molecular abnormalities are being used to screen for potential 
new drugs as well as for targeted treatments 20. Chemotherapeutic drugs are classified by their pharmacologic action and 
their interference with cellular reproduction. They are divided into cell cycle phase-specific and cell cycle phase-
nonspecific. In this review, the mechanism of action of Taxol and Vincristine (vinca alkaloids), chemotherapeutic agents, 
are discussed. 
Natural Products in Cancer Chemotherapy 
There are many ways to treat cancer medicinally. Surgery, radiotherapy, chemotherapy and immunotherapy are the most 
common treatments to choose. Among these cancer treatment methods, chemotherapy is a relatively new one that can 
destroy cancer cells by stopping them from growing or multiplying 21. Healthy cells can also be affected by 
chemotherapeutic agents, especially the rapidly dividing cells. However, these cells has own repair mechanisms and self-
editing. Occasionally, combination chemotherapy of drugs has been used at the same time due to the strong efficiency 
against many types of cancer. Chemotherapy agents, classified into several broad categories according to chief mechanism 
of action, could be used for patients either before “neoadjuvant” or after surgery “adjuvant” 21. 
Identified as DNA interactive agents, Alkylating agents are medicines that directly damage the DNA inside cancer cells. 
These agents act against non-Hodgkin’s lymphoma, leukemia, multiple myeloma, Hodgkin's disease and specific cancer 
types such as breast, lung and ovary in all phases of the cell cycle. Cisplatin, busulfan, cyclophosphamide, 
mechlorethamine, carboplatin, ifosfamide, chlorambucil, melphalan and dacarbazine (DTIC) have been denominated as 
examples of alkylating agents 22. 
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Antimetabolites are able to disrupt nuclei acid synthesis either by falsely substituting for biosynthetic precursors of 
DNA/RNA or by inhibition of normal precursor biosynthesis. These agents could be applied during the S phase for many 
kinds of cancers such as leukemia, tumors of the breast, ovary and the gastrointestinal tract. Examples of antimetabolites 
include methotrexate, 5-fluorouracil, gemcitabine, capecitabine, fludarabine and cytarabine 23. 
 Antitumor antibiotics interfere with DNA by stopping enzymes needed for cell division or by altering the membranes that 
surround cells. These drugs can further work in all phases of the cell cycle. Thus, they are excessively used for diversity 
types of cancers. Daunorubicin, doxorubicin, dactinomycin, mitoxantrone and idarubicin have been determined as 
antitumor antibiotics agents 24. 
 Hormonal agents, which are often  natural or synthetic  hormonal  substances such as steroids, steroid  analogs  or  
hormone-like  compounds,  interact  with hormone receptors to reduce tumors whose growth are sensitive to hormonal 
controls. Tamoxifen is one of the hormone receptor targeting drugs that is applied in the treatment of both early and 
advanced ER+ (estrogen receptor positive) breast cancer 25, 26. Food and Drug Administration (FDA) has been approved to 
use Tamoxifen for the prevention of breast cancer in women at high risk of developing the disease. This agent works in G0 
and G1 phases. 
Antimitotic agents are essentially mitotic inhibitors and act by interfering with the cellular mechanism of mitosis. These 
drugs work during the M phase of the cell cycle. Paclitaxel, docetaxel, etoposide, vinblastine, vincristine, and vinorelbine 
have been characterized as Antimitotic agents 27. This class will be discussed in more details in the following text. 
Endophytic fungi could be alternative approaches for discovery of novel drugs 28. Chemotherapeutic agents obtained from 
endophytic fungi have been examined and they showed acute efficiency against diverse kinds of cancer. Following, the 
mechanisms of the two cancer chemotherapeutic agents isolated from endophytic fungi. 
Paclitaxel and Vincristine Mechanisms of Action 
Due to its unique mode of action compared to other anticancer drugs, the diterpenoid taxol, known as paclitaxel, isolated 
from endophytic fungus Taxus brevifolia, have attracted more attention than any other new drug since its discovery 29,31. 
Paclitaxel (Taxol) is the world’s first billion dollar anticancer drug and is used to treat a number of human tissue 
proliferative diseases 32. Paclitaxel product has been approved by the Food and Drug Administration (FDA) for use in the 
treatment of breast, lung and resistant ovarian cancer 33. Several researches regarding anticancer properties of paclitaxel 
were reported since its discovery as well as the production of paclitaxel has been investigated in the last decade [34-36].  
Paclitaxel (Fig 1) is a complex diterpene having a taxane ring with a 4-membered oxetane ring and an ester side chain at 
position C-13 37. 
Described as major fundamental components in cells, microtubules are among the most successful targets for anticancer 
therapy agents 38. Microtubules are formed through the lateral association of between 12 and 17 tubulin protofilaments, 
which arrange to form a very stiff and hollow filament structure. Microtubules are also highly dynamic, undergoing rapid 
cycles of polymerization and depolymerization 39 
Microtubules are not static but they are highly dynamic polymers and exhibit two kinds of dynamic behaviors: dynamic 
“instability” and “treadmilling”(Fig 2 A, B) 40. These dynamic actions are essential to mitosis phase by which new cells 
are formed from chromosomal division. Microtubule dynamics are highly regulated during the cell cycle by endogenous 
cellular regulators 41. 
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Fig. 1. Structure of 
paclitaxel (Taxol) 
[42]. 
  
Fig .2. (A) Dynamic Treadmilling.              (B) Dynamic Instability 
The action of mode for Paclitaxel (taxol™), taxotere™, laulimalide, sarcodictyins and eleutherobins have been recognized 
by stimulation microtubule polymerization and stabilization of microtubules at high concentrations (Fig 3), whereas the 
inhibition of tubulin-microtubule polymerization has been carried out by cryptophycins vincristine (vinca alkaloids), 
halichondrins, colchicine and estramustine 43,47.  
 
Fig .3. Mechanism of action of paclitaxel  
Regarding lower concentration, these agents have been characterized to possess a popular mechanism through suppression 
of the microtubules dynamics effectively without altering noticeably in the microtubules mass 41.  Moreover, these drugs 
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bind to diverse sites on tubulin and at different positions within the microtubule, and they have diverse effects on 
microtubule dynamics 48. However, by their common action of suppression microtubule dynamics, these antitumor drugs 
can block mitosis at the metaphase or anaphase transition, and induce cell death 49. 
Vincristine (Oncovin ®) (Fig 4) was extracted from Fusarium oxysporum. Described as antimitotic agent that is widely 
used in cancer treatment, Vincristine belongs to the general group of chemotherapy drugs 50, 51. Food and Drug 
Administration (FAD) has approved to use vincristine as anticancer agent in 1963 and is still one of the most 
chemotherapeutic agents administered in the clinic 52. 
Vincristine possesses anti-tumor activity against a wide range of neoplasms including the Hodgkin’s and non-Hodgkin’s 
lymphomas, acute lymphoblastic leukemia, rhabdomyosarcoma, embryonal, neuroblastoma, breast carcinoma, and Wilm’s 
tumor 53, 54. 
 
Fig.4. Structure of Vincristine (Vinca alkaloids) [55]. 
The vincristine (vinca alkaloids) binds to tubulin dimers at a specific recognition site on the protein. The formation of 
paracystalline, which is realized by tubulin- drug complex, has a critical role in the reducing concentration of the dimers 
and pushes the equilibrium between growth and shrinking of the microtubules in favor of shrinking (Fig 5). Cells which 
are subjected to vincristine lose the ability to drive growth correctly in mitosis phase because of poorly formed mitotic 
spindles. The damaged cells then go through apoptosis stage 56. 
 
Fig.5. Mechanism of action of vincristine 
CONCLUSION  
Endophytic fungi produce natural products with a large diversity of chemical structures that would be useful for specific 
medicinal and biotechnological applications. Most of these secondary metabolites exhibit biological activities in 
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pharmaceutically relevant bioassay systems and represent potential lead structures which could be optimized to yield 
effective therapeutic and bioactive agents. Cancer chemotherapy is the use of drugs to kill cancer cells. Conventional 
chemotherapy targets have been the cell cycle, microtubules and DNA. Microtubules and tubulin have been classified as 
the single best cancer target for numerous of anticancer drugs. The mechanism of action of paclitaxel (taxol) has been 
recognized by stimulation microtubule polymerization and stabilization of microtubules whereas vincristine (vinca 
alkaloids) binds to tubulin dimers at a specific recognition site causing inhibition of the microtubules polymerization. 
Significant evidence indicates that the chemotherapeutic drugs have a common model of action; they suppress the 
microtubule dynamics without appreciably changing in the mass of microtubules resulting to block the cell cycle at the 
metaphase or anaphase transition and persuading apoptosis. 
CONFLICT OF INTEREST STATEMENT  
 We declare that we have no conflict of interest 
REFERENCES 
1. Demain A. Pharmaceutically active secondary metabolites of microorganisms. Applied microbiology and 
biotechnology 1999; 54: 455-463. 
2. Keller, NP,Turner G, Bennett JW. Fungal secondary metabolism from biochemistry to genomics. Nature 
Reviews Microbiology 2005; 3: 937-947. 
3. Strobel G. Harnessing endophytes for industrial microbiology. Current opinion in microbiology. 2006; 9: 240-
244. 
4. Porras-Alfaro A, Bayman P. Hidden fungi, emergent properties: endophytes and microbiomes. Phytopathology 
2011; 49: 291-315. 
5. Joseph B, Priya R. Phytochemical and biopharmaceutical aspects of Psidium guajava (L.) essential oil: a review. 
Research Journal of Medicinal Plants 2011; 5: 432-442. 
6. McAlpine JB, Bachmann  BO, Piraee M, Tremblay S, Alarco AM, Zazopoulos E, Farnet CM. Microbial 
genomics as a guide to drug discovery and structural elucidation: ECO-02301, a novel antifungal agent, as an 
example. Journal of natural products 2005; 68: 493-496. 
7. Joseph B, Helen RPP, Sujatha, S. Bio-active compounds in essential oil and its effects of antimicrobial, cytotoxic 
activity from the Psidium guajava (L.). Leaf. J. Adv. Biotechnol 2010; 9: 10-14. 
8. Lam KS. New aspects of natural products in drug discovery. Trends in microbiology 2007; 15: 279-289. 
9. Joseph B, Priya RM. Bioactive compounds from endophytes and their potential in pharmaceutical effect: a 
review.  Am. J. Biochem. Mol. Biol 2011; 1: 291-309. 
10. Strobel G, Daisy B. Bioprospecting for microbial endophytes and their natural products. Microbiology and 
Molecular Biology Reviews 2003; 67: 491-502. 
11. Li, J, Zhao GZ, Chen HH, Wang HB, Qin S, Zhu WY, Xu LH, Jiang CL, Li WJ. Antitumour and antimicrobial 
activities of endophytic streptomycetes from pharmaceutical plants in rainforest. Letters in applied microbiology 
2003; 47: 574-580. 
12. Tan R, Zou W. Endophytes: a rich source of functional metabolites. Natural product reports 2001; 18: 448-459. 
13. Strobel G1, Daisy B, Castillo U, Harper J. Natural Products from Endophytic Microorganisms. Journal of natural 
products 2004; 67: 257-268. 
Almatar et. al. 
Int. J. Curr. Pharm. Rev. Res., Vol. 6, Issue1, 80-88 
 
 
IJCPR, Volume 6, Issue 1, January-February 2015 
P
ag
e8
6
 
14. Verma VC, Kharwar RN, Strobel GA. Chemical and functional diversity of natural products from plant 
associated endophytic fungi. Natural product communications 2009; 4: 1511-1532. 
15. Stierle A, Strobel G, Stierle D.  Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of 
Pacific yew. Science 1993; 260: 214-216. 
16. Zhang HW, Song YC, Tan RX. Biology and chemistry of endophytes. Natural product reports 2006; 23: 753-
771. 
17. Xu LJ, Zhou LG, Zhao JL, Jiang WB. Recent Studies on the Antimicrobial Compounds Produced by Plant 
Endophytic Fungi. Natural Product Research & Development 2004; 20:731. 
18. Baba AI, Câtoi C. Comparative Oncology. The Publishing House of the Romanian Academy Bucharest, 2007. 
19. Firer MA, Gellerman G. Targeted drug delivery for cancer therapy: the other side of antibodies.  J Hematol Oncol 
2012; 5: 1-16. 
20. DeVita VT, Chu E. A history of cancer chemotherapy. Cancer research 2008; 68: 8643-8653. 
21. Huzil JT, Ludueña RF, Tuszynski J. Comparative modelling of human β tubulin isotypes and implications for 
drug binding. Nanotechnology 2006; 17: 90-100. 
22. Rummel M. Considerations with newer regimens for indolent non-Hodgkin lymphoma. Clinical Lymphoma. 
Myeloma & Leukemia 2008; 8: 128-136. 
23. Ewald B, Sampath D, Plunkett W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 
2008; 27: 6522-6537. 
24. Galm U, Hager MH, Van Lanen SG, Ju J, Thorson JS, Shen B. Antitumor antibiotics: bleomycin, enediynes, and 
mitomycin. Chemical reviews 2005;105 :739-758. 
25. American Society of Hospital Pharmacists. Published by authority of the Board of Directors of the American 
Society of Hospital Pharmacists 1989. 
26. Love RR. Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects. Journal of clinical 
oncology 1989;7: 803-815. 
27. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. 
Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 2008; 1785: 96-132. 
28. Firáková S, Šturdíková M, Múčková  M. Bioactive secondary metabolites produced by microorganisms 
associated with plants. Biologia 2007; 62: 251-257. 
29. Gangadevi V, Muthumary J. Taxol, an anticancer drug produced by an endophytic fungus Bartalinia 
robillardoides Tassi, isolated from a medicinal plant, Aegle marmelos Correa ex Roxb. World Journal of 
Microbiology and Biotechnology 2008; 24: 717-724. 
30. Stierle A, Strobel G, Stierle D, Grothaus P, Bignami G. The search for a taxol-producing microorganism among 
the endophytic fungi of the pacific yew, Taxus brevifolia. Journal of natural products 1995; 58:1315-1324. 
31. Wani MC, Taylor HL, Wall ME, Cogon P, McPhail AT. Plant antitumor agents. VI. Isolation and structure of 
taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. Journal of the American Chemical 
Society 1971; 93: 2325-2327. 
32. Vennila R, Kamalraj S, Muthumary J. In vitro studies on anticancer activity of fungal taxol against human breast 
cancer cell line MCF-7 cells. Biomedicine & Aging Pathology 2012; 2:16-18. 
33. Cremasco M, Hritzko, B, Linda Wang NH. Experimental purification of paclitaxel from a complex mixture of 
taxanes using a simulated moving bed. Brazilian Journal of Chemical Engineering 2009; 26: 207-218. 
Almatar et. al. 
Int. J. Curr. Pharm. Rev. Res., Vol. 6, Issue1, 80-88 
 
 
IJCPR, Volume 6, Issue 1, January-February 2015 
P
ag
e8
7
 
34. Lu H, Li B, Kang Y, Jiang W, Huang Q, Chen Q, Li L, Xu C. Paclitaxel nanoparticle inhibits growth of ovarian 
cancer xenografts and enhances lymphatic targeting. Cancer chemotherapy and pharmacology 2007; 59:175-
181. 
35. Kakolyris S, Agelidou A, Androulakis N, Tsaroucha E, Kouroussis CH, Agelidou, M, Karvounis N, Veslemes 
M, Christophylakis CH, Argyraki A, Geroyianni A, Georgoulias V. Cisplatin plus etoposide chemotherapy 
followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage 
small cell lung carcinoma. Lung cancer 2006; 53:59-65. 
36. Peltier S, Oger JM, Lagarce F, Couet W, Benoît JP. Enhanced oral paclitaxel bioavailability after administration 
of paclitaxel-loaded lipid nanocapsules, Pharmaceutical research 2006; 23:1243-1250. 
37. Perez EA . Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action. 
clinical activity, and resistance, Molecular cancer therapeutics 2009; 8: 2086-2095. 
38. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nature Reviews Cancer 2004; 4: 253-265. 
39. Kerssemakers  JW1, Munteanu EL, Laan L, Noetzel TL, Janson ME, Dogterom, M. Assembly dynamics of 
microtubules at molecular resolution. Nature 2006; 442 :709-712. 
40. Bailey M, Conway L, Gramlich MW, Hawkins TL, Ross JL. Modern methods to interrogate microtubule 
dynamics. Integrative Biology 2013; 5: 1324-1333. 
41. Jordan M. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Current Medicinal 
Chemistry-Anti-Cancer Agents  2002, ; 2: 1-17. 
42. Priyadarshini K, Keerthi Aparajitha U. Paclitaxel Against Cancer: A Short Review. Medicinal Chemistry 2012; 
2: 139-141. 
43. Hamel E, Covell DG. Antimitotic peptides and depsipeptides. Current Medicinal Chemistry-Anti-Cancer Agents 
2002; 2: 19-53. 
44. Lacey  E,  Gill J. Biochemistry of benzimidazole resistance. Acta tropica  1994 ; 56: 245-262. 
45. Azarenko O, Okouneva T, Singletary KW, Jordan MA, Wilson L.  Suppression of microtubule dynamic 
instability and turnover in MCF7 breast cancer cells by sulforaphane. Carcinogenesis 2008; 29: 2360-2368. 
46. Lobert S, Ingram JW, Correia JJ. Additivity of dilantin and vinblastine inhibitory effects on microtubule 
assembly. Cancer research  1999; 59: 4816-4822. 
47. Buey RM, Barasoain I, Jackson E, Meyer A, Giannakakou P, Paterson I,  Mooberry, S, Andreu JM, Díaz JF. 
Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel 
site predicts cytotoxicity. Chemistry & biology 2005; 12:1269-1279. 
48. Stec-Martyna E, Ponassi M, Miele M, Parodi S, Felli L, Rosano C. Structural comparison of the interaction of 
tubulin with various ligands affecting microtubule dynamics. Current cancer drug targets 2005; 12: 658-666. 
49. Jordan MA, Toso JR, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by 
taxol at low concentrations. Proceedings of the National Academy of Sciences 1993; 90: 9552-9556. 
50. Kumar A, Patil D, Rajamohanan PR, Ahmad A. Isolation, Purification and Characterization of Vinblastine and 
Vincristine from Endophytic Fungus Fusarium oxysporum Isolated from Catharanthus roseus. PloS one 2013; 
8: e71805. 
51. Donehower R, Rowinsky E. Anticancer drugs derived from plants. Cancer: principles and practice of oncology. 
Pennsylvania: Lippincott 1993: 409-17. 
Almatar et. al. 
Int. J. Curr. Pharm. Rev. Res., Vol. 6, Issue1, 80-88 
 
 
IJCPR, Volume 6, Issue 1, January-February 2015 
P
ag
e8
8
 
52. Thibault K, Rivals I, M'dahoma S, Dubacq S, Pezet S, Calvino B. Structural and Molecular Alterations of 
Primary Afferent Fibres in the Spinal Dorsal Horn in Vincristine-Induced Neuropathy in Rat. Journal of 
Molecular Neuroscience 2013; 51: 880-892. 
53. Carter S, Livingston R. Plant products in cancer chemotherapy. Cancer treatment reports 1976; 60: 1141-1156. 
54. Dahanukar S, Kulkarni R, Rege N. Pharmacology of medicinal plants and natural products. Indian Journal of 
Pharmacology 2000; 32: 81-118. 
55. Boman NL, Bally  MB, Culllis PR, Mayer LD, Webb MS. Encapsulation of vincristine in liposomes reduces its 
toxicity and improves its anti-tumor efficacy. Journal of Liposome Research 1995; 5:523-541. 
56. Drukman S, Kavallaris M. Microtubule alterations and resistance to tubulin-binding agents (Review). 
International Journal of Oncology 2002;  21: 621-628. 
